3 completed. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Completed 3 |
Follow SCF Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of 2.0g Daily of MAG-EPA on the AA/EPA Ratio and Inflammation Biomarkers in a Healthy Population Aged of 50+. Eicosapentaenoic acid monoglycerid (MAG-EPA) - Inflammation | Phase 4 | Completed | SCF Pharma | 30 | 2021-04-21 | 2023-11-27 |
| Comparative Study of Three Different Formulations of Omega-3 (EPA+DHA) MAG-EPA/MAG-DHA, TG-EPA/TG-DHA, EE-EPA/EE-DHA - Healthy Adults | Phase 4 | Completed | SCF Pharma | 36 | 2019-12-18 | 2021-04-29 |
| Effect of Omega-3 Index on Cellular Metabolism and Quality of Life MAG-EPA - Healthy | Phase 4 | Completed | SCF Pharma | 16 | 2017-10-02 | 2019-04-04 |
Inflammation (1)
1-eicosapentaenoylglycerol (2)
Canada (3)
Anne-Julie Landry, MSc (1) · Samuel C Fortin, PhD (1) · Samuel Fortin, PhD (1)